Strides Pharma Science moves up as its arm enters into strategic product development partnership with Kenox
Strides Pharma Science is currently trading at Rs. 885.10, up by 4.05 points or 0.46% from its previous closing of Rs. 881.05 on the BSE.
The scrip opened at Rs. 896.95 and has touched a high and low of Rs. 897.00 and Rs. 885.00 respectively. So far 1742 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 971.90 on 29-Jul-2025 and a 52 week low of Rs. 530.70 on 27-Jan-2025.
Last one week high and low of the scrip stood at Rs. 913.80 and Rs. 878.00 respectively. The current market cap of the company is Rs. 8195.54 crore.
The promoters holding in the company stood at 28.30%, while Institutions and Non-Institutions held 41.33% and 30.37% respectively.
Strides Pharma Science’s step-down wholly owned subsidiary -- Strides Pharma Global, Singapore has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. (Kenox), a fast-growing contract development and manufacturing company specializing in Orally Inhaled and Nasal Drug Products (OINDPs).
Under the terms of the agreement, Strides will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications. The partnership will advance a pipeline of nasal spray products for the US market, combining Strides’ commercial strengths with Kenox’s OINDP expertise to deliver affordable, high-quality therapies to patients.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
